Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Acquires $25,668.80 in Stock

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Director Erin Parsons acquired 5,260 shares of Kiora Pharmaceuticals stock in a transaction on Thursday, June 13th. The shares were bought at an average cost of $4.88 per share, with a total value of $25,668.80. Following the completion of the transaction, the director now owns 5,260 shares of the company’s stock, valued at $25,668.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kiora Pharmaceuticals Trading Up 10.7 %

KPRX stock opened at $5.36 on Friday. The business’s fifty day moving average price is $5.47 and its two-hundred day moving average price is $5.42. Kiora Pharmaceuticals, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, May 10th. The company reported $3.42 EPS for the quarter, missing analysts’ consensus estimates of $5.58 by ($2.16). The company had revenue of $16.00 million for the quarter, compared to analyst estimates of $16.00 million. Equities analysts predict that Kiora Pharmaceuticals, Inc. will post 0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

KPRX has been the subject of a number of research reports. Maxim Group upgraded shares of Kiora Pharmaceuticals to a “strong-buy” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Kiora Pharmaceuticals in a report on Monday, May 20th.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals makes up about 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 22nd largest holding. Rosalind Advisors Inc. owned approximately 8.76% of Kiora Pharmaceuticals at the end of the most recent quarter. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.